Although I still believe that Sanofi would want to use Unifills...

Although I still believe that Sanofi would want to use Unifills for Lovenox .One of the problems I have had is that the patent expiry is before any unifill product could hit the market .The original patent expires this year on 14 Feb. However here have been a number of patent challenges which have been succesfull due to sanofi being found to have engaged in inequitable conduct in filing the patent
http://en.wikipedia.org/wiki/Enoxaparin_sodium
and at least one generic version is apparently available .
Sanofi faces a second the Lovenox generic in the United States, indicating an acceleration of the fall of global sales already-26% in first 9 months of 2011
Sanofi faces a second the Lovenox generic in the United States. Lovenox (enoxaparin), a drug stars of the Sanofi group that generated worldwide sales $ 4.28 billion in 2010 must be faced with the arrival of a second generic of the product in the United States. After the approval of the first generic of the Lovenox in May 2011, marketed by Sandoz, Amphastar Group received approval by the Food and Drug Administration to market a generic version of the Lovenox ahead of Teva, the world leader in the market of generic; The reached a second generic should greatly accelerate erosion of a product deemed as difficult to copy Lovenox saw its global sales erode 26% over the first nine months of 2011 for $ 1.6 billion euros.
Just for emphasis
Lovenox saw its global sales erode 26% over the first nine months of 2011 for $ 1.6 billion euros.
http://health-med-news.com/health/sanofi-faces-a-second-the-lovenox-generic-in-the-united-states-indicating-an-acceleration-of-the-fall-of-global-sales-already-26-in-first-9-months-of-2011/

A product relaunch in a new sexy syringe would seem to be the way to go.

I cannot prove the following part with references but about 12 months ago I saw lovenox on Sanofis web site drugs under development page it’s no longer there